- We are excited to announce that OncoKB™ now includes germline variant annotation on our website\!
  - This release includes 2649 pathogenic or likely pathogenic germline variants across 109 cancer-associated genes.
  - Upcoming releases will incorporate therapeutic implications for germline variants and support for germline variant annotation through the API.
  - To support this expansion, we have introduced a **new gene page layout** that
    clearly separates somatic and germline content. See [BRCA1](/gene/BRCA1/germline) as an example.
  - For more details on germline variant curation, please refer to our updated SOP, _PART II. Germline Variant annotation in OncoKB™_ in v6.0 of the [OncoKB™ SOP](https://sop.oncokb.org/).
- Release of [OncoKB™ SOP v6.0](https://sop.oncokb.org/)
- Transcripts have been updated for the following genes (note, only RefSeq transcripts have changed, not Ensembl transcripts):

<details>
<summary>View details for updated transcripts</summary>

| Gene    | Old Transcript(s)              | Updated Transcript(s)                     |
| :------ | :----------------------------- | :---------------------------------------- |
| ANKRD26 | NM_001256053 (GRCh37/GRCh38)   | NM_014915.2 (GRCh37) NM_014915.3 (GRCh38) |
| TMEM127 | NM_001193304.2 (GRCh37/GRCh38) | NM_017849.3 (GRCh37) NM_017849.4 (GRCh38) |
| MUTYH   | NM_012222.2 (GRCh37)           | NM_001128425.1 (GRCh37)                   |

</details>

<br/>

**Updated Therapeutic Implications**

- Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene  | Mutation                                                                                                                                                                                             | Cancer Type                | Level-Associated Drug(s) in OncoKB™                                                                                                                                              | Drug(s) Added to OncoKB™                    | Evidence                                                                                                                                                                                                                                         |
| :---- | :---- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------------------------------------ | :----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1     | ERBB2 | Tyrosine Kinase Domain Activating Mutations (L726F/I, T733I, L768S, L755A/P/S/W, I767M, D769H/Y, V773L, G776S/V, V777L/M, V794M, T798M, D808N, G815R, D821N, L841V, V842I, L866M, L869R, 770_831ins) | Non-Small Cell Lung Cancer | Trastuzumab Deruxtecan, Zongertinib (Level 1\)<br/><br/>Ado-Trastuzumab Emtansine (Level 2\)<br/><br/>Neratinib, Sevabertinib, Trastuzumab \+ Pertuzumab \+ Docetaxel (Level 3A) | Sevabertinib (Level 1, previously Level 3A) | [FDA approval of sevabertinib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-non-squamous-non-small-cell-lung-cancer); PMID: [41104928](https://pubmed.ncbi.nlm.nih.gov/41104928/) |

- Addition of 18 new genes:
  - ALDH1A3
  - ANK1
  - APOBEC3B
  - ATG5
  - BABAM2
  - BCL9L
  - BIRC5
  - BRD2
  - BRD9
  - CCAR1
  - CCNB1IP1
  - CEP43
  - CHCHD7
  - CILK1
  - CLIP1
  - KDSR
  - LASP1
  - MLF1
